Allogeneic blood or bone-marrow transplantation (alloBMT) is a potentially curative
treatment for a variety of haematological malignancies and nonmalignant diseases …

Hematopoietic stem cell transplantation (HSCT) is the standard treatment for patients with
high-risk hematologic malignancies. Only approximately 25% of siblings are HLA-matched …

The question of the best donor type between haploidentical (HAPLO) and matched-related
donors (MRD) for patients with advanced HL receiving an allogeneic hematopoietic cell …

When a person seeks to purchase a product in the marketplace, be it a car or an apple, 2
product characteristics are decisive: price and quality. If a customer perceives 2 varieties of …

Introduction: Post transplant cyclophosphamide (PT/Cy) in association to other
immunosuppressive agents or alone has emerged as a promising pharmacological strategy …

Allogeneic stem cell transplantation (allo-SCT) following a non-myeloablative (NMA) or
reduced-intensity conditioning (RIC) is considered a valid approach to treat patients with …

Background: Despite therapeutic progress, 10 to 30% of adult patients with primary
mediastinal B cell lymphoma (PMBCL) are primary refractory or experience early relapse …

Unmanipulated haploidentical transplantation (Haplo-SCT) using post-transplantation
cyclophosphamide (PT-Cy) represents an alternative for patients with high-risk diseases …

Allogeneic stem cell transplantation (alloSCT) continues to be the only potentially curative
treatment for patients with refractory lymphomas or relapsing after autologous stem cell …

T-cell replete Haploidentical stem cell transplantation (Haplo-SCT) with Post-transplant
cyclophosphamide (PT-Cy) is an emerging therapeutic option for patients with advanced …